Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ABT | COURT-RULING | neutral | 2/10 | Two separate employment discrimination lawsuits against Abbott Laboratories (ABT) resulted in procedural rulings on the | Oct 15, 2026 |
| TCRT | SC 13D/A | neutral | 6/10 | Robert W. Postma and WaterMill Asset Management Corp. filed an amended Schedule 13D disclosing a 9.99% beneficial owners | Oct 15, 2026 |
| ORKA | CLUSTER | neutral | 3/10 | Two insiders at Oruka Therapeutics sold a total of ~$380K in open-market sales over a one-week window. The CMO sold $211 | Oct 15, 2026 |
| REGN | ANALYST-UPGRADE | bullish | 7/10 | UBS double-upgraded REGN from Neutral to Buy on October 15, 2026, raising the price target to $978 from $660, a 48% incr | Oct 15, 2026 |
| MPLT | 144 | neutral | 2/10 | Jonathan Gillis, an officer of MapLight Therapeutics, filed a Form 144 notice of intent to sell 10,167 shares of common | Oct 15, 2026 |
| CRSP | CLUSTER | neutral | 3/10 | CEO Samarth Kulkarni and General Counsel James Kasinger sold a combined $253K in CRSP stock on October 14, 2026, at $49. | Oct 15, 2026 |
| SGMOQ | 8-K | bearish | 7/10 | Sangamo Therapeutics filed its Chapter 11 monthly operating report for August 2026, showing a net loss of $14.4 million | Oct 15, 2026 |
| RXRX | 424B5 | bearish | 6/10 | Recursion Pharmaceuticals is offering 61,540,000 shares of Class A common stock at $3.25 per share, raising approximatel | Oct 15, 2026 |
| TENX | SC 13G/A | neutral | 3/10 | Millennium Management LLC filed an amended Schedule 13G disclosing a 3.6% passive stake in Tenax Therapeutics as of Sept | Oct 15, 2026 |
| MPLT | 144 | neutral | 2/10 | Christopher A. Kroeger, an officer of MapLight Therapeutics, filed a Form 144 notice of intent to sell 73,691 shares of | Oct 15, 2026 |
| ERNA | 8-K | neutral | 2/10 | Ernexa Therapeutics Inc. filed an 8-K on October 15, 2026, disclosing that it made an investor presentation available. T | Oct 15, 2026 |
| IRD | 8-K | bullish | 6/10 | Opus Genetics presented positive interim clinical data from its OPGx-BEST1 and OPGx-LCA5 gene therapy programs at Retina | Oct 15, 2026 |
| BHVN | 8-K | bullish | 7/10 | Biohaven entered a strategic licensing agreement with Ono Pharmaceutical for its MoDE pan IgG degrader portfolio (BHV-13 | Oct 15, 2026 |
| MPLT | 144 | neutral | 2/10 | Lillie James Woodruff, an officer of MapLight Therapeutics, filed a Form 144 notice of intent to sell 11,513 shares of c | Oct 15, 2026 |
| ATNM | 8-K | neutral | 3/10 | Actinium Pharmaceuticals appointed Matt David, M.D. as CFO, effective October 14, 2026. Dr. David brings extensive bioph | Oct 15, 2026 |
| NRIX | CLUSTER | neutral | 3/10 | Nurix Therapeutics director Julia P. Gregory executed a same-day derivative exercise and open-market sale of 22,583 shar | Oct 15, 2026 |
| OLMA | 8-K | neutral | 2/10 | Olema Pharmaceuticals disclosed the resignation of board member Dr. Gorjan Hrustanovic, effective October 14, 2026, who | Oct 15, 2026 |
| BMRA | 8-K | neutral | 2/10 | Board member David Moatazedi will not stand for re-election at Biomerica's 2026 Annual Meeting on December 11, 2026, and | Oct 15, 2026 |
| SXTC | SC 13G | neutral | 3/10 | Orca Capital AG disclosed a passive 9.9% stake in China SXT Pharmaceuticals via a Schedule 13G, holding 1,112,788 Class | Oct 15, 2026 |
| ALXO | 8-K | mixed | 6/10 | ALX Oncology entered into exchange agreements with major stockholders (Blackstone, RA Capital, venBio) to surrender 13,3 | Oct 15, 2026 |
| CGON | 144 | neutral | 2/10 | Director Leonard Post filed a Form 144 to sell 3,000 shares of CG Oncology common stock, with an estimated aggregate mar | Oct 15, 2026 |
| KRSA | SC 13G/A | neutral | 2/10 | J. Wood Capital Advisors LLC filed an amended Schedule 13G disclosing a passive stake of 25,974 shares (0.1%) in Korsana | Oct 15, 2026 |
| NTHI | 8-K | neutral | 3/10 | NeOnc Technologies announced the resignation of director Dr. Steven Giannotta and the appointment of Ali Alabedin, Head | Oct 15, 2026 |
| TRAX | 8-K | bearish | 6/10 | First Tracks Biotherapeutics entered into a securities purchase agreement to sell 6,106,870 shares of common stock at $3 | Oct 15, 2026 |
| CBIO | 8-K | neutral | 3/10 | Crescent Biopharma provided a clinical pipeline update via an 8-K, announcing that the Phase 1/2 ASCEND trial of CR-001 | Oct 15, 2026 |
| PRTA | INSIDER-BUY | bullish | 5/10 | 10% owner William P. Scully purchased 100,000 shares of Prothena Corp for $835K in an open-market transaction on October | Oct 15, 2026 |
| AVXL | 8-K | neutral | 4/10 | Anavex received FDA clearance to proceed with its IND for blarcamesine in Fragile X syndrome, enabling a Phase 2a study | Oct 15, 2026 |
| KRSA | DEF 14A | neutral | 5/10 | Korsana Biosciences is resubmitting a proposal to redomesticate from Massachusetts to the Cayman Islands at a special me | Oct 15, 2026 |
| CBIO | PRESS-RELEASE | neutral | 4/10 | Crescent Biopharma provided a clinical pipeline update, highlighting completion of dose escalation in the global Phase 1 | Oct 15, 2026 |
| VRXA | 6-K | neutral | 4/10 | Veraxa Biotech presented first in vivo proof-of-concept data for its BiTAC-ADC platform at the World ADC Congress, showi | Oct 15, 2026 |